Back to Intelligence Hub
DEAcritical impact AI CURATED

DEA Heightens Scrutiny on Online Prescribing of Controlled Substances, Including GLP-1s

The Drug Enforcement Administration (DEA) is intensifying its focus on telehealth providers prescribing controlled substances without proper in-person evaluations, particularly in the context of medications like GLP-1s. This trend signals a renewed emphasis on the Ryan Haight Act and its exceptions, requiring practitioners to ensure legitimate medical purpose and patient safety in virtual care settings.

April 17, 20269 viewsSource: Drug Enforcement Administration (DEA)

DEA Intensifies Scrutiny on Online Prescribing of Controlled Substances

The Drug Enforcement Administration (DEA) has signaled a renewed and intensified focus on the online prescribing of controlled substances, a trend that carries significant implications for telehealth providers across various specialties. This heightened scrutiny underscores the DEA's commitment to preventing diversion and ensuring patient safety, particularly as the healthcare landscape continues to integrate virtual care models.

Understanding the Regulatory Framework: The Ryan Haight Act

At the core of DEA's oversight of online prescribing is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. This federal law generally requires that a practitioner conduct at least one in-person medical evaluation of a patient before prescribing a controlled substance. The Act was a direct response to the proliferation of

Original Source

https://www.deadiversion.usdoj.gov/pubs/docs/telemed_qa.htm

This article was generated by AI based on the source above and reviewed for accuracy. Always verify critical compliance decisions with qualified legal counsel.

Affected Specialties

weight-losshormone-therapymental-healthsexual-healthprimary-carelongevityurgent-carepain-managementmedspafunctional-medicine

Need Compliance Help?

Our team can help you understand how this regulatory change affects your specific business.

Get Started

Share This Update

Back to Regulatory Intelligence Hub